Evidence-Based Genetic Tests
Evidence-Based Genetic Tests
Rainbow Genomics is committed to providing clinically-validated and affordable genetic tests to patients in Asia. We specialize in providing whole-exome-sequencing & pharmacogenomics tests, enabling individuals and their physicians to use genomic information for diagnosis, treatment and disease prevention.
We deliver clinical interpretations specifically for Asians, based on expert understanding of their genetics, and medical care experience in the Hong Kong, Japan and the United States.
Coupled with our industry-first "Double Interpretation", provided simultaneously by U.S. and Japanese medical Institutions, we target unique Asian genetics to improve overall diagnostic yield.
Rainbow Genomics is a Hong Kong- & U.S.-based genetic test and information company, with operations in Hong Kong, Japan and the U.S. Our management and clinical advisory teams consist of genetics, health care, ethics and public policy experts with substantial research and clinical experience. We have contracted with the following partners & providers to deliver clinically-validated tests following ACMG (American College of Medical Genetics and Genomics) guidelines.
" Physician Reports Issued By U.S. Board-Certified Medical Directors"
Most of our genetic tests are based on clinical whole-exome-sequencing technology.
To assure highly accurate test results, DNA sequencing is performed at CAP-accredited or CLIA-certified laboratories.
Data analysis and clinical interpretation are performed by the UCLA Clinical Genomics Center and Baylor Genetics, both are among the largest and oldest genetic testing laboratories in the U.S. Their board-certified medical directors will issue physician reports.
We also work closely with OneOme, a U.S. company established by Invenshure and Mayo Clinic, to provide a comprehensive pharmacogenomics test covering over 340 medications.
In addition, we partner with Consultagene from Baylor College of Medicine to provide genetic counseling to patients, and peer-to-peer consultation to physicians.
Our Primary Product -
Clinical Whole Exome Sequencing tests
Our Primary Product -
Clinical Whole Exome Sequencing tests
The human genome consists of 3 billion nucleotides or “letters” of DNA. Only a small fraction, about 1.5% of the genome, contains genes that encode proteins, which control various functions in the body. Much of what we know about genetic disorders are based on these genes, or what we collectively called the exome. An exome contains more than 22,000 genes.
The Rainbow whole exome sequencing tests analyze over 22,000 genes, and provide clinical reports that are based on clear medical evidence.
Most direct-to-consumer tests provide hundreds or even thousands of genetic findings that lack clinical utilities. Unlike these "recreational genetic tests", the Rainbow whole exome sequencing tests provide clinically- actionable results related to disorders for which your physicians can manage, treat or prevent.
One exome supports clinical interpretation on multiple conditions. With exome sequencing data covering over 22,000 genes, patients can request to receive clinical interpretation on additional conditions not originally ordered by their physicians.
For example, a patient who received a Rainbow Cardio Test can subsequently request to be tested for cancer predisposition risk using Rainbow Wellness Cancer Test. Because we already have the whole exome data, the patient can receive a cancer screening test report within two weeks, without incurring the cost of DNA sequencing again.
Unlike many genetic tests using a small number of genes (1-200 genes in a fixed panel), Rainbow utilizes the entire exome for analysis and clinical interpretation. Analyzing the entire exome reduces the risk of not including sufficient Asian specific genes. This is a concern because many of these gene panels were designed based on clinical studies using Caucasian patients in the U.S. and Europe. There is often insufficient evidence to confirm the clinical utilities of these genes for Asian patients. Whole exome sequencing test reduces this risk.
As new genetic variants are discovered, especially by Asian clinicians, and more variants of uncertain clinical significance (VUS) are reclassified as pathogenic or likely-pathogenic mutations, we can provide timely reports for previously-unresolved clinical cases. This is feasible because we sequence over 22,000 genes for each patient.
Clinical interpretation provided by the UCLA Clinical Genomics Center and Baylor Genetics follows the current ACMG (American College of Medical Genetics and Genomics) guidelines. The UCLA Clinical Genomics Center and Baylor Genetics also issue physician reports signed-off by their board-certified medical directors.
Clinical exome sequencing performed at either CAP (College of American Pathologists) accredited or CLIA (Clinical Laboratory Improvement Amendments) certified laboratories.
Patient data privacy – Rainbow follows the U.S. Health Insurance Portability and Accountability Act (HIPAA) privacy rules, established to protect the confidentiality of patients' individually identifiable health information.
Additional clinical interpretation provided by the Saitama Medical University or Juntendo University is in compliance with Japan’s clinical testing guidelines
UCLA & Baylor
UCLA & Baylor
Rainbow Genomics contracts with the UCLA Clinical Genomics Center.
Utilizing our expertise in Pediatrics, Human Genetics, and Pathology, the UCLA Clinical Genomics Center provides a comprehensive analysis and diagnostic interpretation of a patient's entire protein-encoding genome by searching through 37 million base pairs in 20,000 genes to potentially locate the single DNA change responsible for the patient's disorder.
Our approach to data interpretation is unparalleled. Raw data is filtered through our bioinformatics pipeline and variants are selected for review by our Genomic Data Board. Our Board is comprised of an interdisciplinary team of professionals and includes input from the patient's clinician. Our Board's expertise and experience assures the most thorough evaluation of each patient's data.
Baylor Genetics, an affiliate of the #1 NIH-funded genetics program at Baylor College of Medicine, has been a pioneer of precision medicine for nearly 40 years. Today, we offer a full spectrum of cost-effective genetic testing providing clinically relevant solutions. Our unmatched experience delivers a combination of advanced technology, deep patient data sets, and genetic talent that leads accurate interpretations of the most complex cases.
The clinical utility of our tests and the care we take to educate providers and patients is in our DNA. We’re complemented by the entire Baylor College of Medicine staff of medical geneticists, faculty, genetic counselors, and researchers who help us drive discoveries and testing. By bridging academic and operational excellence, Baylor Genetics offers the medical community an extensive testing menu, access to world-renowned experts, and the confidence to provide patients with answers.
Baylor Genetics, located in Houston’s Texas Medical Center, serves clients in 50 states and 16 countries. Connect with us via our website (bmgl.com), Twitter (@baylorgenetics), Facebook (facebook.com/baylorgenetics), or LinkedIn (linkedin.com/company/baylorgenetics).
OneOme was established by Invenshure and Mayo Clinic to provide a comprehensive, cost-effective pharmacogenomic solution integrated into patients’ everyday clinical care.
OneOme’s key product offering is the RightMed® pharmacogenomic test, a physician-ordered genetic test that predicts how a patient’s DNA and current prescriptions may affect their response to medications.
The analysis is provided to the physician in the form of static and interactive reports that identifies which prescription drugs are — or aren’t — likely to work.
This information can help providers make better prescription decisions, protect patients from adverse drug reactions and drug ineffectiveness, and reduce healthcare costs.
Our mission is to deliver the most cost-effective, comprehensive, clinically actionable pharmacogenomic (PGx) testing and tools for all providers and patients worldwide.
As a product of the Department of Molecular and Human Genetics at Baylor College of Medicine in collaboration with Baylor Genetics, Consultagene leverages the intellectual capital of the department's faculty, 180 members strong, and healthcare providers.
This group includes the following:
Education. Access educational videos, pamphlets, and web-based resources that are personally selected by experts to fit your situation and your genetic health concerns.
Genetic Counseling. In-depth counseling with one of our certified genetic counselors through our secure, self-scheduled portal to answer your genetic health questions and to connect you with the next steps.
Daniel C. Siu
Mr. Siu is the founder and CEO of Rainbow Genomics. He brings 28 years of experience in genetics and life science business to the company.
Prior to Rainbow, Mr. Siu co-founded Nextcode Health, a bioinformatics company spun off by Amgen and deCODE Genetics. Nextcode was acquired by WuXi for US$65M after one year in operations. Prior to Nextcode, Mr. Siu co-founded Axeq Technologies. Axeq subsequently merged its 200 client accounts with Macrogen, to become the world's largest next-generation-sequencing service provider. From 2005-2011, he was the managing director at deCODE Genetics, growing their genomic services business into a market leader worldwide.
Mr. Siu received his B.S. in molecular biology from the University of Texas, Austin; his M.S. in bioinorganic chemistry from the University of Minnesota, Minneapolis; and his MBA from San Francisco State University.
Yasushi Okazaki, M.D, Ph.D.
Dr. Okazaki is a pioneer and a leader in using precision medicine and next-generation-sequencing tests for hereditary disorders and tumor care in Japan. He currently holds multiple positions -
Dr. Okazaki is the head & professor of Diagnostics and Therapeutics of Intractable Diseases, Graduate School of Medicine, & the Intractable Disease Research Center, at Juntendo University.
In addition, Dr. Okazaki is the facility director of RIKEN Genome Network Analysis Support Facility leading their research DNA sequencing efforts.
He is also a visiting professor at the Research Center for Genomic Medicine, Saitama Medical University.
Dr. Okazaki is a pioneer in Japan using genomics technologies in clinical care, including the applications of whole exome sequencing in pediatric and emergency neonatal care, and cancer panel sequencing for tumor profiling. He also leads multiple cancer screening projects for Japanese patients. Dr. Okazaki is frequently interviewed by the Japanese media and corporations, on current practices of precision medicine and how it may impact the Japanese society.
Dr. Okazaki received his M.D. from Okayama University Medical School, and his Ph.D. from Osaka University Medical School.
Clinical Advisory Board
Clinical Advisory Board
Scott W. Binder, M.D.
Dr. Scott Binder retired from UCLA Health as the Pritzker Professor & Senior Vice Chair; Director, Pathology Clinical Services; Chief, Dermatopathology in January, 2018. He is now the director at the Binder Institute of Pathology, Los Angeles.
At UCLA Health, Dr. Binder directed all of the clinical and anatomic laboratories, the Autopsy Service, the Biomarker Innovations Laboratory, the Cytogenetics Laboratory, the Molecular Pathology Laboratory and the Clinical Genomics Center.
Dr. Binder is a nationally and internationally known dermatopathologist with one of the largest consultative practices in the country. He receives more than 6,000 second opinion consults on difficult and challenging cases in dermatopathology from academic institutions, reference laboratories and community pathology groups from all over the country as well as international cases from Greece, China, and Korea.
Dr. Binder has devoted a great deal of time to research in the molecular signatures of tumors with an emphasis on using unique gene expressions to diagnose and prognosticate various dermatologic neoplasms. His working team has won two Stowell-Orbison awards at USCAP, two years in a row. The first award concerned the use of gene signatures using microarray technology to characterize cellular neurothekeomas of the skin. The second award was based on a study which compared metastases of melanoma with their primaries and shed light upon which genes may be important in predicting which melanomas will metastasize to sentinel lymph nodes, and thus, which melanomas may demonstrate a worse clinical prognosis.
Dr. Binder has given many talks in China, where he was inducted to the Chinese Academy of Medical Sciences.
Recently, Dr. Binder was introduced to a Chinese environmental testing company, CTI, which wanted to expand into medical laboratory testing. Since then, Dr. Binder and the partners have planned a lab in Shanghai China, which will specialize in esoteric testing for clinical trials and clinical work for Chinese hospitals and other less advanced labs. The lab building, approximately 25,000 sq. ft., is being outfitted in Shanghai, and the choice of instrumentation and technologists is well underway. This lab should greatly elevate the quality of care for patients and doctors in China, and has served as an excellent springboard for learning how business is conducted in China.
Wayne W. Grody, M.D., Ph.D.
Dr. Grody is a professor in the Departments of Pathology & Laboratory Medicine, Pediatrics and Human Genetics, and the institute for Society and Genetics, at the UCLA School of Medicine.
He is the director of the Molecular Diagnostic Laboratories and the Clinical Genomics Center within the UCLA Medical Center, one of the first such facilities in the country to offer DNA-based tests for diagnosis of a wide variety of genetic, infectious, and neoplastic diseases, as well as bone marrow engraftment, patient specimen identification and paternity testing by DNA fingerprinting, and clinical genomic DNA sequencing for undiagnosed disorders.
Dr. Grody is also an attending physician in the Department of Pediatrics, specializing in the care of patients with or at risk for genetic disorders (with a special interest in familial Mediterranean fever, among others), and director of the UCLA Intercampus Medical Genetics Training Program.
He has been one of the primary developers of quality assurance and ethical guidelines for DNA-based genetic testing for a large number of governmental and professional agencies including the FDA, AMA, CAP, ACMG, ASHG, NCCLS/CLSI, CDC, AMP, VA, ACGME, NIH-DOE Human Genome Project (ELSI program).
He also served -
Dr. Grody did his undergraduate work at Johns Hopkins University, received his M.D. and Ph.D. at Baylor College of Medicine, and completed residency and fellowship training at UCLA. He is double-board-certified by the American Board of Pathology (Anatomic and Clinical Pathology, molecular Genetic Pathology) and the American Board of Medical Genetics (Clinical Genetics, Molecular Genetics, Biochemical Genetics).
Dr. Stephen Tak Sum Lam
Between 1990-2015, Dr. Lam was the Director of Genetic Laboratory and Head of Clinical Genetic Service, Department of Health, Hong Kong. Over these 25 years, Dr. Lam was instrumental in training many clinical geneticists and teaching physicians who are currently serving various communities in Hong Kong as clinicians and faculty members at university medical schools - Dr. Lam is often referred to as "the grandfather of medical genetics in Hong Kong" .
His main clinical activities and research are in the diagnosis and prevention of genetic diseases and ethical, legal and social issues in genetics. He has published more than 100 articles and edited two books.
Dr. Lam is currently the Director of Clinical Genetics Service and Honorary Consultant in Clinical Genetics in the Hong Kong Sanatorium and Hospital. He is also an Honorary Professor of the Faculty of Medicine in the Chinese University of Hong Kong. In addition, Dr. Lam is also -
Dr. Lam serves as Convenor of the Ethics Panel of the Hong Kong Family Planning Association and as a member on the Ethics Committee of the Council on Human Reproductive Technology in Hong Kong. He also serves as editor of several international journals including Clinical Genetics, HUGO Journal, and Journal of Community Genetics.
Dr. Lam was also the -
Dr. Lam obtained his Bachelor of Medicine and Bachelor of Surgery degrees from the University of Hong Kong in 1976. Subsequently, he was trained in Paediatrics and Clinical Genetics at Queen Elizabeth Hospital, Hong Kong and Guy's Hospital, London. For his research on Biochemical Genetics and Cytogenetics, he was awarded Doctor of Medicine in 1988. He was awarded Master of Health Administration from the University of New South Wales in 1997.
Brendan Lee, M.D., Ph.D.
Dr. Lee is the Robert and Janice McNair Endowed Chair in Molecular and Human Genetics, Professor and Chairman of the Department of Molecular and Human Genetics at Baylor College of Medicine.
As a pediatrician and geneticist, Dr. Lee studies structural birth defects and inborn errors of metabolism. Dr. Lee identified the first genetic causes of human skeletal dysplasias. In the area of metabolic disease, he has developed new treatments for maple syrup urine disease and urea cycle disorders.
Dr. Lee has been recognized by election to
He has also been awarded
Dr. Lee was previously an Investigator of the Howard Hughes Medical Institute prior to his appointment as Chair of the Department of Molecular and Human Genetics in 2014.
The Department of Molecular and Human Genetics at Baylor College of Medicine, is the leading genetics program integrating basic, translational, clinical, and diagnostic laboratory activities. It is composed of over 180 primary faculty members encompassing research, clinical, laboratory diagnostic, and genetic counseling missions. It ranks number one in total NIH funding and number of NIH grants.
Jason Merker, M.D., Ph.D.
Dr. Merker is Co-Director of the Stanford Medicine Clinical Genomics Program, a joint effort between Stanford Children’s Health, Stanford Health Care, and the Stanford University School of Medicine.
The Clinical Genomics Program is a clinical and laboratory service that uses genome and exome sequencing as well as other advanced molecular testing to assist in the diagnosis of genetic disease.
Dr. Merker received his M.D. and Ph.D. in Genetics from the University of North Carolina at Chapel Hill. He then completed residency training in Clinical Pathology and fellowship training in Molecular Genetic Pathology and Clinical Cytogenetics at Stanford Hospital and Clinics, followed by post-doctoral training in cancer genomics at Stanford University.
Dr. Merker also directs an active research group that focuses on two areas: 1.) development of improved experimental and computational approaches related to the use of genomic sequencing and other “omics” assays for clinical care, and 2.) identification and characterization of acquired and heritable genetic variants that are important for the development of hematologic disorders and other malignancies.
Rainbow Genomics is majority-owned by its founder, management team and employees. We maintain 100% freedom to develop high-quality and credible genetic tests for patients and healthy individuals in Asia. We are committed to supporting physicians in local communities throughout Asia Pacific.
Rainbow Genomics maintains operations in the U.S. and Hong Kong.
Our English-speaking, Hong Kong-based project managers work closely with ordering physicians all over Asia to collect patient samples, manage testing process, and coordinate physician report delivery.
Our partner laboratories, U.S. and Japanese medical institutions support the entire clinical testing process.
Our partner genetic counselors and physicians based in Hong Kong, Shenzhen (China), and the U.S. provide bilingual (English with Japanese, Mandarin or Cantonese) genetic counseling to our patients, and consultation to physicians in local communities.